Leukocyte cell therapy - Macrocure

Drug Profile

Leukocyte cell therapy - Macrocure

Alternative Names: CureXcell

Latest Information Update: 14 Dec 2015

Price : $50

At a glance

  • Originator MacroCure
  • Class Cell therapies; Skin disorder therapies
  • Mechanism of Action Growth substance stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Chronic wounds; Skin ulcer
  • Phase III Diabetic foot ulcer; Leg ulcer

Most Recent Events

  • 12 May 2015 Phase-III development for Diabetic foot ulcer is ongoing in USA, Canada and Israel
  • 11 May 2015 MacroCure completed enrolment in a phase III trial for Leg ulcer (Adjunctive treatment) in USA
  • 01 Feb 2015 Pharmacodynamics data from a preclinical trial in Chronic wounds released by MacroCure
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top